Recent Progress in the Oral Delivery of Therapeutic Peptides and Proteins: Overview of Pharmaceutical Strategies to Overcome Absorption Hurdles

Overview

Journal Adv Pharm Bull

Date 2024 Apr 8

PMID 38585454

Authors

Sonal Mehrotra

Pavan Kalyan Bg

Pawan Ganesh Nayak

Alex Joseph

Jyothsna Manikkath

Affiliations

Soon will be listed here.

Abstract

Purpose: Proteins and peptides have secured a place as excellent therapeutic moieties on account of their high selectivity and efficacy. However due to oral absorption limitations, current formulations are mostly delivered parenterally. Oral delivery of peptides and proteins (PPs) can be considered the need of the hour due to the immense benefits of this route. This review aims to critically examine and summarize the innovations and mechanisms involved in oral delivery of peptide and protein drugs.

Methods: Comprehensive literature search was undertaken, spanning the early development to the current state of the art, using online search tools (PubMed, Google Scholar, ScienceDirect and Scopus).

Results: Research in oral delivery of proteins and peptides has a rich history and the development of biologics has encouraged additional research effort in recent decades. Enzyme hydrolysis and inadequate permeation into intestinal mucosa are the major causes that result in limited oral absorption of biologics. Pharmaceutical and technological strategies including use of absorption enhancers, enzyme inhibition, chemical modification (PEGylation, pro-drug approach, peptidomimetics, glycosylation), particulate delivery (polymeric nanoparticles, liposomes, micelles, microspheres), site-specific delivery in the gastrointestinal tract (GIT), membrane transporters, novel approaches (self-nanoemulsifying drug delivery systems, Eligen technology, Peptelligence, self-assembling bubble carrier approach, luminal unfolding microneedle injector, microneedles) and lymphatic targeting, are discussed. Limitations of these strategies and possible innovations for improving oral bioavailability of protein and peptide drugs are discussed.

Conclusion: This review underlines the application of oral route for peptide and protein delivery, which can direct the formulation scientist for better exploitation of this route.

Citing Articles

GPCR drug discovery: new agents, targets and indications.

Lorente J, Sokolov A, Ferguson G, Schioth H, Hauser A, Gloriam D Nat Rev Drug Discov. 2025; .

PMID: 40033110 DOI: 10.1038/s41573-025-01139-y.

Engineering non-pathogenic bacteria for auto-transporter-driven secretion of functional interferon.

Tfilin Samuel M, Rostovsky I, Kuzmina A, Taube R, Sal-Man N Gut Microbes. 2025; 17(1):2474146.

PMID: 40032826 PMC: 11881866. DOI: 10.1080/19490976.2025.2474146.

Systematic review of peptide nanoparticles for improved diabetes outcomes: insights and opportunities.

Dangana R, Okon M, Orire I, Sanusi I, Terkimbi S, Aja P Discov Nano. 2025; 20(1):41.

PMID: 39961878 PMC: 11832960. DOI: 10.1186/s11671-025-04215-9.

Basil seed mucilage as a bioadhesive polymer: Development of naproxen sodium microspheres and suppositories with and studies.

Tripathi D, Rathour K, Pandey P, Kumar Tiwari R, Rai A ADMET DMPK. 2024; 12(6):881-901.

PMID: 39713257 PMC: 11661803. DOI: 10.5599/admet.2372.

Optimization, physicochemical stability and in vivo study of alginate-chitosan composites as nanocarriers for low molecular weight angiotensin I-converting enzyme (ACE)-inhibitory peptide.

Auwal S, Ghanisma S, Saari N J Food Drug Anal. 2024; 32(3):358-370.

PMID: 39636769 PMC: 11464040. DOI: 10.38212/2224-6614.3522.

References

Craik D, Fairlie D, Liras S, Price D . The future of peptide-based drugs. Chem Biol Drug Des. 2012; 81(1):136-47. DOI: 10.1111/cbdd.12055. View

Yang T, Arnold J, Ahsan F . Tetradecylmaltoside (TDM) enhances in vitro and in vivo intestinal absorption of enoxaparin, a low molecular weight heparin. J Drug Target. 2005; 13(1):29-38. DOI: 10.1080/10611860400020191. View

Brayden D, Jepson M, Baird A . Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. Drug Discov Today. 2005; 10(17):1145-57. DOI: 10.1016/S1359-6446(05)03536-1. View

Bies C, Lehr C, Woodley J . Lectin-mediated drug targeting: history and applications. Adv Drug Deliv Rev. 2004; 56(4):425-35. DOI: 10.1016/j.addr.2003.10.030. View

Evans D, Pye G, Bramley R, Clark A, Dyson T, Hardcastle J . Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988; 29(8):1035-41. PMC: 1433896. DOI: 10.1136/gut.29.8.1035. View

Lindmark T, Schipper N, Lazorova L, De Boer A, Artursson P . Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes. J Drug Target. 1998; 5(3):215-23. DOI: 10.3109/10611869808995876. View

Li P, Nielsen H, Mullertz A . Impact of Lipid-Based Drug Delivery Systems on the Transport and Uptake of Insulin Across Caco-2 Cell Monolayers. J Pharm Sci. 2016; 105(9):2743-2751. DOI: 10.1016/j.xphs.2016.01.006. View

Kiela P, Ghishan F . Physiology of Intestinal Absorption and Secretion. Best Pract Res Clin Gastroenterol. 2016; 30(2):145-59. PMC: 4956471. DOI: 10.1016/j.bpg.2016.02.007. View

Cao S, Xu S, Wang H, Ling Y, Dong J, Xia R . Nanoparticles: Oral Delivery for Protein and Peptide Drugs. AAPS PharmSciTech. 2019; 20(5):190. PMC: 6527526. DOI: 10.1208/s12249-019-1325-z. View

10.

Zhu Q, Chen Z, Paul P, Lu Y, Wu W, Qi J . Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharm Sin B. 2021; 11(8):2416-2448. PMC: 8424290. DOI: 10.1016/j.apsb.2021.04.001. View

11.

Lowman A, Morishita M, Kajita M, Nagai T, Peppas N . Oral delivery of insulin using pH-responsive complexation gels. J Pharm Sci. 1999; 88(9):933-7. DOI: 10.1021/js980337n. View

12.

Wright L, Barnes T, Prestidge C . Oral delivery of protein-based therapeutics: Gastroprotective strategies, physiological barriers and in vitro permeability prediction. Int J Pharm. 2020; 585:119488. DOI: 10.1016/j.ijpharm.2020.119488. View

13.

Bansil R, Turner B . The biology of mucus: Composition, synthesis and organization. Adv Drug Deliv Rev. 2017; 124:3-15. DOI: 10.1016/j.addr.2017.09.023. View

14.

Woodley J . Enzymatic barriers for GI peptide and protein delivery. Crit Rev Ther Drug Carrier Syst. 1994; 11(2-3):61-95. View

15.

Friedrichsen G, Nielsen C, Steffansen B, Begtrup M . Model prodrugs designed for the intestinal peptide transporter. A synthetic approach for coupling of hydroxy-containing compounds to dipeptides. Eur J Pharm Sci. 2001; 14(1):13-9. DOI: 10.1016/s0928-0987(01)00137-3. View

16.

Lopes M, Abrahim B, Cabral L, Rodrigues C, Seica R, Veiga F . Intestinal absorption of insulin nanoparticles: contribution of M cells. Nanomedicine. 2014; 10(6):1139-51. DOI: 10.1016/j.nano.2014.02.014. View

17.

Khan M, Roberts M . Challenges and innovations of drug delivery in older age. Adv Drug Deliv Rev. 2018; 135:3-38. DOI: 10.1016/j.addr.2018.09.003. View

18.

des Rieux A, Fievez V, Garinot M, Schneider Y, Preat V . Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release. 2006; 116(1):1-27. DOI: 10.1016/j.jconrel.2006.08.013. View

19.

Tanaka K, Fujita T, Yamamoto Y, Murakami M, Yamamoto A, Muranishi S . Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. Biochim Biophys Acta. 1996; 1283(1):119-26. DOI: 10.1016/0005-2736(96)00087-9. View

20.

Abu-Qarn M, Eichler J, Sharon N . Not just for Eukarya anymore: protein glycosylation in Bacteria and Archaea. Curr Opin Struct Biol. 2008; 18(5):544-50. DOI: 10.1016/j.sbi.2008.06.010. View